High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy
| العنوان: | High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy |
|---|---|
| المؤلفون: | Narisa Dewi Maulany Darwis, Yuya Yoshimoto, Norichika Ota, Takahiro Oike, Hiro Sato, Ken Ando, Tatsuya Ohno |
| المصدر: | Japanese Journal of Radiology. 40:534-541 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cervical cancer, medicine.medical_specialty, Multivariate analysis, business.industry, medicine.medical_treatment, Uterine Cervical Neoplasms, Retrospective cohort study, Prognosis, medicine.disease, Radiation therapy, medicine.anatomical_structure, Germline mutation, Internal medicine, Biomarkers, Tumor, medicine, Humans, Biomarker (medicine), Female, Radiology, Nuclear Medicine and imaging, business, Immune Checkpoint Inhibitors, Lymph node, Definitive radiotherapy, Retrospective Studies |
| الوصف: | Purpose Tumor mutational burden (TMB) is a surrogate biomarker of neo-antigens and high TMB status is associated with favorable response to immune-checkpoint inhibitors (ICIs). This study aimed to elucidate the association between TMB and the outcome of definitive radiotherapy in patients with cervical cancer. Materials and methods TMB and treatment outcome were retrospectively analyzed in patients with newly diagnosed cervical cancer treated with definitive radiotherapy available with somatic mutation data of pre-treatment tumors obtained using a commercially available gene panel. Results The study enrolled 98 patients (median follow-up period, 61 months). The median TMB was 9.5 mutations per megabase (range, 3.0–35.5 mutations per megabase). After dichotomization based on this median value, the 5-year overall survival (OS) for TMB-high patients was significantly worse than that of TMB-low patients (61.1% vs. 82.2%). Multivariate analysis identified high TMB status as a significant prognostic factor for worse OS, along with advanced stage, para-aortic lymph node involvement, and absence of concurrent chemotherapy. Conclusion These data indicate that TMB is a potential prognostic factor for worse survival in patients with cervical cancer treated with definitive radiotherapy, thereby providing a rationale for treatment of TMB-high cervical cancers with a combination of ICIs plus radiotherapy. Secondary abstract This retrospective study of 98 patients demonstrates for the first time that tumor mutational burden (TMB) is an independent prognostic factor for worse overall survival of patients treated with definitive radiotherapy, providing a rationale for treatment of TMB-high cervical cancers with a combination of immune-checkpoint inhibitors plus radiotherapy. |
| تدمد: | 1867-108X 1867-1071 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b019801f8ff1043c78e242b82275b2Test https://doi.org/10.1007/s11604-021-01230-5Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e9b019801f8ff1043c78e242b82275b2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1867108X 18671071 |
|---|